Sensitive ASO Quantitation for Decentralized Trials
In this poster presentation, our scientific team demonstrates the promising future of blood microsampling in decentralized clinical trials to support the development of antisense therapeutic drugs.
Find out how they achieved precision, accuracy, and linearity within acceptance criteria with our sensitive and selective bioanalytical method for determining ASOs. Covering an analytical range of 0.50 – 500 ng/ml, they used dried blood micro-samples collected via the Capitainer® qDBS (10 µL), and analyzed them using hybridization LC-MS/MS.
You may also be interested in the following:
- Microsampling: When Small Steps Lead to Big Outcomes
- Coupling Hybridization LC-MS Workflows With Microsampling
- Sparking the Evolution of Microsampling With the Mitra® VAMS® Device